Expert Voices in Dementia

Mar 21 2025 18 ep. 13 mins 131
Expert Voices in Dementia Podcast artwork

Thought leaders from the field present insights from dementia research, clinical practice, and caregiving that will help you maximize the quality of life and well-being of your patients

  Science  Health & Fitness  Education
RSS feed Share
Copy RSS


Subscribe on Podcast Addict


Plasma P-Tau217: Detecting Alzheimer Disease with a Blood Test

Mar 21 2025 20 mins  
Sterling Johnson, PhD, Associate Director and Biomarker Core Leader in the Wisconsin Alzheimer’s Disease Research Center (ADRC), and a Clinical Neuropsychologist and Neuroscientist focused on understanding AD-related changes in the brain, details his research into the use of plasma p-tau217 as a blood-based biomarker for detecting Alzheimer disease. Learn more about your ad choic

Updated Criteria for Diagnosis and Staging of Alzheimer Disease: Recommendations of the International Working Group

Feb 25 2025 11 mins  
Nicolas Villain, MD, PhD, Associate Professor of Neurology, Sorbonne University, Paris, France, discusses the International Working Group’s updated diagnostic criteria for the diagnosis and staging of Alzheimer disease, which offer an alternative definitional view of AD as a clinical-biologic construct. Learn more about your ad choices. Visit megaphone.fm/adchoices

Blarcamesine: An Investigational Oral Drug for Alzheimer Disease

Jan 25 2025 16 mins  
Timo Grimmer, MD, Associate Professor of Psychiatry and Psychotherapy and Head of the Centre for Cognitive Disorders at the Technical University of Munich, Germany, discusses the experimental oral small molecule drug blarcamesine, which is under investigation as a potential treatment for Alzheimer disease. Learn more about your ad choices. Visit megaphone.fm/adchoices

The CMS GUIDE Model To Support Patients with Dementia and Their Caregivers

Dec 19 2024 10 mins  
Sarena Ho, Health Insurance Specialist at the CMS Innovation Center, provides an overview on the Guiding an Improved Dementia Experience (GUIDE) Model, which helps physicians provide coordinated care to support patients with dementia and their caregivers. Learn more about your ad choices. Visit megaphone.fm/adchoices

The BenfoTeam Clinical Trial: Investigating Benfotiamine as a Potential Therapy for Early Alzheimer Disease

Nov 19 2024 15 mins  
Gary E. Gibson, PhD, Professor of Neurosciences, Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, details his research related to metabolic changes associated with Alzheimer disease and a clinical trial studying the effects of benfotiamine therapy on cognitive and other outcomes. Learn more about your ad choices. Visit megaphone.fm/adchoices

BrainCheck as a Digital Cognitive Assessment Tool

Nov 08 2024 7 mins  
Kim Rodriguez, CEO of BrainCheck, provides an overview of the company's cognitive assessment plan and how clinicians can use these tools in practice. Learn more about your ad choices. Visit megaphone.fm/adchoices

Kramer, Van Dyck

Sep 27 2024 12 mins  
Lynn D. Kramer, MD, FAAN, Chief Clinical Officer, Deep Human Biology Learning at Eisai and a member of the Eisai Executive Committee, and Christopher van Dyck, MD, Professor of Psychiatry, Neurology, and Neuroscience, Yale School of Medicine, provide an overview of key results from the Clarity AD clinical trial assessing the safety and efficacy of lecanemab in people with early Alz

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 3

Sep 21 2024 10 mins  
In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this epi

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 2

Sep 21 2024 17 mins  
In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this epi

CSF, PET, and Blood-Based Biomarker Tests for Alzheimer Disease - Part 1

Sep 21 2024 8 mins  
In this series, Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses cerebrospinal fluid, PET, and blood-based biomarker tests for Alzheimer disease, including factors influencing the selection of these tests and recommendations for physicians when communicating test results with their patients. In this epi